Carta Healthcare Enhances Oncology Research with Realyze Intelligence Acquisition
In a significant move to transform oncology research and clinical trials, Carta Healthcare has announced the acquisition of Realyze Intelligence, a company known for its innovative AI-powered solutions. Based in San Francisco, Carta Healthcare focuses on improving healthcare by harnessing the potential of clinical data. With this acquisition, the company aims to bolster its capabilities, particularly in the oncology sector, enabling it to improve the speed and efficiency of matching patients with relevant clinical trials.
Realyze Intelligence is a specialized platform that utilizes clinician-trained artificial intelligence (AI) to swiftly analyze both structured and unstructured data found in electronic health records (EHRs). Traditionally, identifying suitable candidates for clinical trials can be a lengthy process, often taking hours or even days. However, with Realyze's technology, this task can now be accomplished in a matter of seconds. This not only accelerates research but also significantly cuts costs, allowing healthcare providers to allocate resources more effectively.
The efficacy of Realyze's AI solution is evident in its application within leading cancer centers, including its involvement in the Memorial Sloan Kettering Cancer Center Innovation Hub. Furthermore, it was selected for the inaugural CancerX Accelerator Program, underscoring its reputation and reliability in the oncology field. Since its formation in 2020 as part of UPMC Enterprises, Realyze has distinguished itself by merging clinical expertise with advanced AI technologies to derive valuable insights into patient populations.
For example, a noteworthy analysis showed that UPMC Hillman Cancer Center experienced a sevenfold increase in patient matching for trials when using Realyze's software, along with a doubling of enrollments compared to prior periods when the software was not in use. This enhancement in patient enrollment rates reflects Realyze's substantial impact on clinical trial efficiency and accessibility.
In conjunction with Realyze's advanced technology, Carta Healthcare offers its own AI-driven platform, which streamlines the process of data abstraction for clinical registries and research initiatives. By merging these two technologies, the benefits of heightened automation could result in enormous time savings and diminished labor costs for clinical data projects — spanning oncology, cardiovascular health, and other medical specialties.
Brent Dover, CEO of Carta Healthcare, expressed his enthusiasm about the acquisition, stating, "Data is the key ingredient for advancing healthcare practices. Our shared vision with Realyze Intelligence centers on leveraging AI effectively to enhance insights derived from clinical data, thereby improving patient outcomes through efficient clinical trials and comprehensive cancer registries."
Amidst an urgent need for innovation in the healthcare sector, especially as cancer threatens to surpass cardiovascular diseases as the leading global cause of death, organizations are compelled to innovate and enhance interventions. With over 80% of clinical trial eligibility criteria buried within unstructured patient notes, manual extraction remains a common yet inefficient practice. In contrast, approximately 50% of cancer patients are open to participating in clinical trials if properly approached, yet only a fraction (7%) currently do. Carta Healthcare's advanced system, now bolstered by Realyze Intelligence, seeks to bridge this gap by simplifying trial feasibility and expediting the research process.
Aaron Brauser, CEO of Realyze Intelligence, highlighted the financial strain and labor-intensive nature of patient recruitment for clinical trials, pointing out that healthcare systems and pharmaceutical firms invest billions in this area annually. He emphasized the need for timely, high-quality data that can significantly enhance patient identification processes, which often remains inaccessible due to current inefficiencies. The integration of Realyze's AI technology into Carta Healthcare's system symbolizes a commitment to revolutionize how clinical trials are matched with eligible patients, optimizing care pathways, and ultimately improving healthcare outcomes.
In conclusion, the acquisition of Realyze Intelligence represents a strategic advancement for Carta Healthcare in its mission to transform healthcare through optimized data utilization and AI innovation. This partnership is poised to redefine paradigms in clinical trial operations, allowing for faster patient matching and greater efficiency in oncology research — significantly benefiting healthcare professionals and patients alike.
Realyze Intelligence is a specialized platform that utilizes clinician-trained artificial intelligence (AI) to swiftly analyze both structured and unstructured data found in electronic health records (EHRs). Traditionally, identifying suitable candidates for clinical trials can be a lengthy process, often taking hours or even days. However, with Realyze's technology, this task can now be accomplished in a matter of seconds. This not only accelerates research but also significantly cuts costs, allowing healthcare providers to allocate resources more effectively.
The efficacy of Realyze's AI solution is evident in its application within leading cancer centers, including its involvement in the Memorial Sloan Kettering Cancer Center Innovation Hub. Furthermore, it was selected for the inaugural CancerX Accelerator Program, underscoring its reputation and reliability in the oncology field. Since its formation in 2020 as part of UPMC Enterprises, Realyze has distinguished itself by merging clinical expertise with advanced AI technologies to derive valuable insights into patient populations.
For example, a noteworthy analysis showed that UPMC Hillman Cancer Center experienced a sevenfold increase in patient matching for trials when using Realyze's software, along with a doubling of enrollments compared to prior periods when the software was not in use. This enhancement in patient enrollment rates reflects Realyze's substantial impact on clinical trial efficiency and accessibility.
In conjunction with Realyze's advanced technology, Carta Healthcare offers its own AI-driven platform, which streamlines the process of data abstraction for clinical registries and research initiatives. By merging these two technologies, the benefits of heightened automation could result in enormous time savings and diminished labor costs for clinical data projects — spanning oncology, cardiovascular health, and other medical specialties.
Brent Dover, CEO of Carta Healthcare, expressed his enthusiasm about the acquisition, stating, "Data is the key ingredient for advancing healthcare practices. Our shared vision with Realyze Intelligence centers on leveraging AI effectively to enhance insights derived from clinical data, thereby improving patient outcomes through efficient clinical trials and comprehensive cancer registries."
Amidst an urgent need for innovation in the healthcare sector, especially as cancer threatens to surpass cardiovascular diseases as the leading global cause of death, organizations are compelled to innovate and enhance interventions. With over 80% of clinical trial eligibility criteria buried within unstructured patient notes, manual extraction remains a common yet inefficient practice. In contrast, approximately 50% of cancer patients are open to participating in clinical trials if properly approached, yet only a fraction (7%) currently do. Carta Healthcare's advanced system, now bolstered by Realyze Intelligence, seeks to bridge this gap by simplifying trial feasibility and expediting the research process.
Aaron Brauser, CEO of Realyze Intelligence, highlighted the financial strain and labor-intensive nature of patient recruitment for clinical trials, pointing out that healthcare systems and pharmaceutical firms invest billions in this area annually. He emphasized the need for timely, high-quality data that can significantly enhance patient identification processes, which often remains inaccessible due to current inefficiencies. The integration of Realyze's AI technology into Carta Healthcare's system symbolizes a commitment to revolutionize how clinical trials are matched with eligible patients, optimizing care pathways, and ultimately improving healthcare outcomes.
In conclusion, the acquisition of Realyze Intelligence represents a strategic advancement for Carta Healthcare in its mission to transform healthcare through optimized data utilization and AI innovation. This partnership is poised to redefine paradigms in clinical trial operations, allowing for faster patient matching and greater efficiency in oncology research — significantly benefiting healthcare professionals and patients alike.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.